Multicenter open-label study of parenteral ofloxacin in treatment of pyelonephritis in adults
| Autor: | Guillermo Rodriguez-Gomez, Layne O. Gentry, Clair E. Cox |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Ofloxacin medicine.medical_specialty medicine.drug_class Klebsiella pneumoniae Urology medicine.medical_treatment Antibiotics Administration Oral Gastroenterology Drug Administration Schedule Internal medicine medicine Humans Infusions Parenteral Adverse effect Aged Aged 80 and over Chemotherapy Pyelonephritis biology business.industry Middle Aged biology.organism_classification Rash Surgery Clinical trial Female medicine.symptom business Enterobacter cloacae medicine.drug |
| Zdroj: | Urology. 39:453-456 |
| ISSN: | 0090-4295 |
| DOI: | 10.1016/0090-4295(92)90246-s |
| Popis: | The efficacy and safety of parenteral ofloxacin were evaluated in an open, multicenter study of hospitalized patients with pyelonephritis. The patients received ofloxacin 400 mg IV as an initial dose followed by ofloxacin 200 mg IV b.i.d. for a minimum of three days. The patients could then continue ofloxacin orally 200 mg b.i.d. for a total of seven to fourteen days. The most common pathogens isolated were Escherichia coli, Enterobacter cloacae, and Klebsiella pneumoniae. Microbiologic eradication was achieved in 65 of 66 evaluable patients (98%), and clinical cure or clinical improvement was noted in all patients. Of 82 patients evaluable for safety, 12 (15%) reported drug-related adverse events, the most frequent of which was pruritus or rash. None of the patients experienced drug-related central nervous system symptoms. Ofloxacin is well tolerated and highly effective in the treatment of pyelonephritis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|